We are monitoring the impact of COVID-19 on North America Pancreatic Cancer Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1204
Share on
Share on

North America Pancreatic Cancer Market Research Report – Segmented By Treatment Type, Cancer Type, End Users & Region - Industry Analysis, Size, Share, Growth, Trends & Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1204
Pages: 179

North America Pancreatic Cancer Market Size (2021 to 2026)

The size of the Pancreatic Cancer Market in North America is estimated to grow USD 1.42 billion by 2026 from USD 0.99 billion in 2021, growing at a CAGR of 7.54% during the forecast period.

The market for pancreatic cancer in North America is growing owing to the growing incidence of pancreatic cancer, growing population, and Increasing healthcare expenditure. The Significant rise in the number of people and growing concern about pancreatic cancer across the region propels the market growth. Pancreatic cancer is the 12th most frequent cancer among males and the 11th most common cancer among women globally. The most important factors that increase the risk are tobacco addiction and medical history. Also, Technological advancements in drug development about pancreatic cancer and evolving healthcare infrastructure are boosting the market growth during the forecast period. Growth in the pancreatic cancer therapy market will be driven by the introduction of drugs with novel mechanisms of action across several therapies, which are poised to meet high unmet needs in the US and 5EU. Moreover, the large number of unmet needs related to the disease attracting many multinational companies to invest in this division which is expected to expand the market growth. 

In late-stage pancreatic cancer patients, premium-priced treatments have been introduced in the previous three to four years. The market growth trend in the recent past indicates a shift in market consumption from chemotherapy to targeted treatments, as well as a shift in the treatment paradigm towards personalized medicine methods. Therefore, over the projection period, kinase inhibitors, which comprise many types of pipeline medicines presently under development, are likely to be the pioneers among pipeline agents.

However, high costs associated with the treatment, Inadequate results after treatment, and adverse side-effects are some of the factors restricting the market growth. The other factors, such as Difficulty in diagnosis during the early stages, Low success rates in clinical trials for cancer drugs, and limited treatment options, especially when the disease has spread to other organs or parts of the body, are the growth restraints of the market.

This research report on the North American Pancreatic Cancer Market has been segmented & sub-segmented into the following categories:

By Treatment Type:

  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Other

By Cancer Type:

  • Exocrine Pancreas Cancer
  • Endocrine Pancreas Cancer

By End User:

  • Hospitals
  • Clinics
  • Research Institutes
  • Others

By Country:

  • United States
  • Canada
  • Rest of North America

Geographically, the North American Pancreatic Cancer Market is projected to account for a rapid share during the forecast period. The market growth in the region is attributed to the increase in the incidence of patients with pancreas cancer, increasing healthcare expenditures, and the rising number of therapies launched in the market. In addition, the major companies in the region are conducting research and development activities, and increasing investment for the development of cancer therapeutics centers are most likely to augment the market growth.

Pancreatic cancer is the fourth-largest cause of cancer-related fatalities in the United States, after lung cancer and breast cancer, and the seventh most significant cause of cancer-related global deaths, with 432,242 deaths reported in 2018. The most prevalent type of pancreatic cancer is pancreatic adenocarcinoma (PDAC), which is categorized as an exocrine pancreatic cancer and accounts for 80% of all pancreatic cancer diagnoses. 

The US, however, is still expected to be the market leader in 2029, is valued twice as much as in 2019, thus highlighting interesting market dynamics for this indication based on incidence rates, clinical approaches, and product commercialization.

The Canadian pancreatic cancer market is projected to witness a promising share and contribute to the regional market. 

KEY MARKET PLAYERS:

Companies leading the North American pancreatic cancer market profiled in this report are Eli Lilly, Amgen, Inc., Celgene Corp., F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Novartis AG, Threshold Pharmaceuticals Inc., Aduro BioTech Inc., Infinity Pharmaceuticals Inc., and NewLink Genetics Corp. 

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Type of Treatment                  

                                5.1.1 Introduction           

                                5.1.2 Surgery    

                                5.1.3 Chemotherapy     

                                5.1.4 Radiation Therapy

                                5.1.5 Others      

                                5.1.6 Y-o-Y Growth Analysis, By Type of Treatment          

                                5.1.7 Market Attractiveness Analysis, By Type of Treatment         

                                5.1.8 Market Share Analysis, By Type of Treatment          

                5.2 Type                              

                                5.2.1 Introduction           

                                5.2.2 Exocrine Pancreas Cancer

                                5.2.3 Endocrine Pancreas Cancer              

                                5.2.4 Y-o-Y Growth Analysis, By Type      

                                5.2.5 Market Attractiveness Analysis, By Type     

                                5.2.6 Market Share Analysis, By Type      

                5.3 End-users                   

                                5.3.1 Introduction           

                                5.3.2 Hospitals  

                                5.3.3 Clinics        

                                5.3.4 Research Institutes             

                                5.3.5 Others      

                                5.3.6 Y-o-Y Growth Analysis, By End-users            

                                5.3.7 Market Attractiveness Analysis, By End-users          

                                5.3.8 Market Share Analysis, By End-users           

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Type of Treatment

                                                6.1.3.3 By Type

                                                6.1.3.4 By End-users

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Type of Treatment

                                                6.1.4.3 By Type

                                                6.1.4.4 By End-users

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Type of Treatment

                                                6.1.5.3 By Type

                                                6.1.5.4 By End-users

                6.2 United States                            

                6.3 Canada                         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Eli Lilly                           

                                8.1.1 Overview

                                8.1.2 Type of Product    

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Amgen, Inc.                

                8.3 Celgene Corp.                           

                8.4 F. Hoffmann-La Roche                           

                8.5 Clovis Oncology Inc.                

                8.6 Pfizer                            

                8.7 Novartis AG                

                8.8 Threshold Pharmaceuticals Inc.                          

                8.9 Aduro BioTech Inc.                  

                8.10 Infinity Pharmaceuticals Inc.                             

                8.11 NewLink Genetics Corp.                      

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Surgery Market, By Region, From 2021 to 2026 (USD Billion)
  2. North America Chemotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  3. North America Radiation Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  4. North America Others Market, By Region, From 2021 to 2026 (USD Billion)
  5. North America Pancreatic Cancer Market, By Type, From 2021 to 2026 (USD Billion)
  6. North America Exocrine Pancreas Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  7. North America Endocrine Pancreas Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  8. North America Pancreatic Cancer Market, By End-users, From 2021 to 2026 (USD Billion)
  9. North America Hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  10. North America Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  11. North America Research Institutes Market, By Region, From 2021 to 2026 (USD Billion)
  12. North America Others Market, By Region, From 2021 to 2026 (USD Billion)
  13. United States Pancreatic Cancer Market, By Type of Treatment, From 2021 to 2026 (USD Billion)
  14. United States Pancreatic Cancer Market, By Type, From 2021 to 2026 (USD Billion)
  15. United States Pancreatic Cancer Market, By End-users, From 2021 to 2026 (USD Billion)
  16. Canada Pancreatic Cancer Market, By Type of Treatment, From 2021 to 2026 (USD Billion)
  17. Canada Pancreatic Cancer Market, By Type, From 2021 to 2026 (USD Billion)
  18. Canada Pancreatic Cancer Market, By End-users, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample